Search results for "Equianalgesic"

showing 5 items of 5 documents

Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose

2003

Breakthrough pain is normally severe in intensity and has a rapid onset. The availability of supplemental doses of opioids (rescue medication) in addition to the continuous analgesic medication is the main treatment suggested to manage these pain flares. The intravenous (i.v.) route may provide analgesia fast enough, but has never been assessed in clinical studies. The aim of this open-label study was to verify the safety and effectiveness of an i.v. dose equal to one-fifth the calculated equianalgesic total daily dose in advanced cancer patients with episodic pain. A consecutive sample of 48 cancer patients treated with oral morphine, who reported an acceptable basal analgesia and reported…

MalePalliative careExacerbationSafety and effectiveness of intravenous morphineAnalgesicPainDrug Administration ScheduleOral administrationNeoplasmsmorphine doseMedicineHumansAdverse effectGeneral NursingDose-Response Relationship DrugMorphineepisodic (breakthrough) painbusiness.industryPalliative CareMiddle AgedEquianalgesicAnalgesics OpioidAnesthesiology and Pain MedicineAnesthesiaInjections IntravenousMorphineFemaleNeurology (clinical)businessCancer painmedicine.drug
researchProduct

Intravenous morphine for breakthrough (episodic-) pain in an acute palliative care unit: a confirmatory study.

2007

The aim of this prospective cohort study was to confirm the safety of intravenous morphine (IV-M) used in doses proportional to the basal opioid regimen for the management of breakthrough pain and to record the nurse compliance on regularly recording data regarding breakthrough pain treated by IV-M. Over a one-year period, 99 patients received IV-M for breakthrough pain during 116 admissions. The IV-M dose was 1/5 of the oral daily dose, converted using an equianalgesic ratio of 1/3 (IV/oral). For each episode, nurses were instructed to routinely collect changes in pain intensity and emerging problems when pain became severe (T0), and to reassess the patient 15minutes after IV-M injection (…

MalePalliative carePainCancer pain breakthrough-episodic pain intravenous morphineMedicineHumansProspective StudiesAdverse effectProspective cohort studyGeneral NursingAgedMorphinebusiness.industryPalliative CareMiddle AgedEquianalgesicClinical trialAnalgesics OpioidRegimenAnesthesiology and Pain MedicineOpioidAnesthesiaInjections IntravenousFemaleNeurology (clinical)businessCancer painmedicine.drugJournal of pain and symptom management
researchProduct

Equipotent doses to switch from high doses of opioids to transdermal buprenorphine.

2008

INTRODUCTION: The aim of this study was to evaluate the equianalgesic ratio of transdermal buprenorphine (TD BUP) with oral morphine and TD fentanyl in a sample of consecutive cancer patients receiving stable doses of 120-240 mg of oral morphine or 50-100 microg of TD fentanyl, reporting adequate pain and symptom control. MATERIALS, METHODS, AND RESULTS: Patients receiving daily stable doses of opioids for more than 6 days, with no more than two doses of oral morphine (20 and 40 mg, respectively) as needed, were switched to TD BUP using a fentanyl-BUP ratio of 0.6:0.8 and an oral morphine-BUP ratio of 70:1. Opioid doses, pain and symptom intensity, global satisfaction, and number of breakth…

Maletransdermal buprenorphinePainAdministration CutaneousFentanylNeoplasmsHigh dosesMedicineHumansSymptom controlProspective StudiesOral morphineAgedDose-Response Relationship Drugbusiness.industryMiddle AgedEquianalgesicBuprenorphineAnalgesics OpioidFentanylOncologyPatient SatisfactionAnesthesiaFemaleTransdermal Buprenorphinehigh doses of opioidsbusinessCancer painmedicine.drugSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
researchProduct

Switching from Transdermal Drugs: An Observational "N of 1" Study of Fentanyl and Buprenorphine

2007

The aim of this study was to confirm that the concomitant presence of transdermal fentanyl (TTS FE) and buprenorphine (TTS BU) may be feasible without important consequences, using doses presumed to be equianalgesic. A prospective "N of 1" study was carried out in a sample of volunteers with cancer pain receiving stable doses of TTS FE or TTS BU, with adequate pain and symptom control. In the study design, each patient provided data before and after a switch from one opioid to the other and then back to the previous one. Sixteen patients receiving daily stable doses of 0.6 or 1.2 mg of TTS FE were switched to TTS BU using an FE-BU ratio of 0.6-0.8. After three days, the TTS BU patch was rem…

OralAdultMaletransdermal buprenorphinePainAdministration OralOpioidAdministration CutaneousFentanylopioid switchingNeoplasmsMedicineHumansDosingProspective StudiesCancer painNursing (all)2901 Nursing (miscellaneous)General NursingTransdermalAgedPain MeasurementIntractableAnalgesicsbusiness.industryMiddle AgedEquianalgesictransdermal fentanylBuprenorphinePain IntractableAnalgesics OpioidFentanylCutaneousAnesthesiology and Pain MedicineNeurologyOpioidConcomitantAnesthesiaCancer pain; opioid switching; transdermal buprenorphine; transdermal fentanyl; Administration Oral; Adult; Aged; Analgesics Opioid; Buprenorphine; Female; Fentanyl; Humans; Male; Middle Aged; Neoplasms; Pain Measurement; Pain Intractable; Prospective Studies; Administration Cutaneous; Anesthesiology and Pain Medicine; Neurology (clinical); Neurology; Nursing (all)2901 Nursing (miscellaneous)AdministrationFemaleNeurology (clinical)businessCancer painmedicine.drugBuprenorphine
researchProduct

Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review

2011

In this paper we describe the results of a systematic search of the literature on conversion ratios during opioid switching. This is part of a project of the European Palliative Care Research Collaboration to update the European Association for Palliative Care recommendations for the use of opioid analgesics in the treatment of cancer pain. Studies were eligible for inclusion if they involved adult patients with chronic cancer pain, contained data on opioid conversion ratios, were prospective and were written in English. Thirty-one studies were identified and included. The majority of the studies had methodological flaws and were not designed to explore or demonstrate equianalgesic dose da…

medicine.medical_specialtyPalliative careMEDLINEPainDrug Administration ScheduleFentanylNeoplasmsmedicineHumansDrug Dosage CalculationsDosingIntensive care medicinePain MeasurementRandomized Controlled Trials as TopicDose-Response Relationship Drugbusiness.industryGeneral MedicineEquianalgesicAnalgesics OpioidEuropeAnesthesiology and Pain MedicineOpioidAnesthesiaPractice Guidelines as TopicCancer painbusinessmedicine.drugBuprenorphinePalliative Medicine
researchProduct